JP7492336B2 - 多量体ｉｌ－１５に基づく分子 - Google Patents

多量体ｉｌ－１５に基づく分子 Download PDF

Info

Publication number
JP7492336B2
JP7492336B2 JP2019521081A JP2019521081A JP7492336B2 JP 7492336 B2 JP7492336 B2 JP 7492336B2 JP 2019521081 A JP2019521081 A JP 2019521081A JP 2019521081 A JP2019521081 A JP 2019521081A JP 7492336 B2 JP7492336 B2 JP 7492336B2
Authority
JP
Japan
Prior art keywords
human
cells
domain
txm
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019521081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533449A (ja
JP2019533449A5 (enExample
Inventor
ヒン シー． ウォン，
ウォーレン マーカス，
バイ リウ，
ウェンシン シュ，
ロビー ニューマン，
カレン ケイジ，
リジン ヨウ，
ピーター ロード，
パトリック スン－シオン，
Original Assignee
アルター・バイオサイエンス・コーポレーション
ナントセル，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルター・バイオサイエンス・コーポレーション, ナントセル，インコーポレイテッド filed Critical アルター・バイオサイエンス・コーポレーション
Publication of JP2019533449A publication Critical patent/JP2019533449A/ja
Publication of JP2019533449A5 publication Critical patent/JP2019533449A5/ja
Application granted granted Critical
Publication of JP7492336B2 publication Critical patent/JP7492336B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019521081A 2016-10-21 2017-10-21 多量体ｉｌ－１５に基づく分子 Active JP7492336B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662411216P 2016-10-21 2016-10-21
US62/411,216 2016-10-21
US201762513964P 2017-06-01 2017-06-01
US62/513,964 2017-06-01
PCT/US2017/057757 WO2018075989A1 (en) 2016-10-21 2017-10-21 Multimeric il-15-based molecules

Publications (3)

Publication Number Publication Date
JP2019533449A JP2019533449A (ja) 2019-11-21
JP2019533449A5 JP2019533449A5 (enExample) 2020-10-22
JP7492336B2 true JP7492336B2 (ja) 2024-05-29

Family

ID=62019612

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019521081A Active JP7492336B2 (ja) 2016-10-21 2017-10-21 多量体ｉｌ－１５に基づく分子

Country Status (12)

Country Link
US (3) US20180200366A1 (enExample)
EP (2) EP4613776A3 (enExample)
JP (1) JP7492336B2 (enExample)
KR (2) KR20190091264A (enExample)
CN (2) CN118562016A (enExample)
AU (1) AU2017345791B2 (enExample)
BR (1) BR112019007920A2 (enExample)
CA (2) CA3200275A1 (enExample)
IL (1) IL266100B2 (enExample)
MX (1) MX2019004681A (enExample)
SG (1) SG11201903306SA (enExample)
WO (1) WO2018075989A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743249B (zh) 2007-05-11 2017-08-08 阿尔托生物科学有限公司 融合分子与il‑15变异体
CN112494646A (zh) 2014-06-30 2021-03-16 阿尔托生物科学有限公司 基于il-15的分子及其方法和用途
JP2019519516A (ja) 2016-05-18 2019-07-11 モデルナティーエックス， インコーポレイテッド がんの治療のためのｍＲＮＡ併用療法
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
MA46534A (fr) 2016-10-14 2019-08-21 Xencor Inc Protéines de fusion fc hétérodimères il15/il15r
KR20190091264A (ko) 2016-10-21 2019-08-05 알토 바이오사이언스 코포레이션 다량체 il-15 기반 분자
US11129883B2 (en) * 2017-03-06 2021-09-28 Altor BioScience, LLC. IL-15-based fusions to IL-12 and IL-18
WO2018175310A1 (en) * 2017-03-20 2018-09-27 Cancer Therapeutics Laboratories, Inc. Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
KR20200090742A (ko) 2017-08-28 2020-07-29 알토 바이오사이언스 엘엘씨 Il-7 및 il-21에의 il-15 기반 융합
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
KR20200131867A (ko) * 2018-03-14 2020-11-24 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항-cd33 키메라 항원 수용체 및 이의 용도
KR20210010862A (ko) 2018-04-18 2021-01-28 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
MA52289A (fr) 2018-04-18 2021-02-24 Xencor Inc Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
CA3100282A1 (en) 2018-06-19 2019-12-26 Nantcell, Inc. Hiv treatment compositions and methods
WO2020023713A1 (en) * 2018-07-26 2020-01-30 Nantbio, Inc. Tri-cytokine txm compositions and methods
CN112888445B (zh) * 2018-08-30 2025-06-10 免疫生物公司 治疗老年化相关病症的方法
JP7407822B2 (ja) 2018-08-30 2024-01-04 エイチシーダブリュー バイオロジックス インコーポレイテッド 単鎖キメラポリペプチドおよびその使用
EP4659757A2 (en) 2018-08-30 2025-12-10 ImmunityBio, Inc. Multi-chain chimeric polypeptides and uses thereof
EP3847242A4 (en) * 2018-09-07 2022-06-08 NantBio, Inc. TARGETED IL-12 TREATMENTS AND METHODS TO STIMULATE HANK AND NK92MI CELLS
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CR20210239A (es) 2018-10-12 2021-12-15 Xencor Inc Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
IL316199A (en) 2018-10-31 2024-12-01 Immunitybio Inc Clearance of PD-L1-positive malignancies by NK cells expressing a chimeric PD-L1 antigen receptor
WO2020132646A1 (en) 2018-12-20 2020-06-25 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
EP3908314A4 (en) * 2019-01-11 2023-05-10 Memorial Sloan Kettering Cancer Center MULTIMERIZATION OF IL-15/IL-15R ALPHA-FC COMPLEXES TO IMPROVE IMMUNOTHERAPY
CA3142159A1 (en) * 2019-05-31 2020-12-03 City Of Hope Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies
WO2020257639A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
EP4019536A4 (en) * 2019-08-19 2023-09-06 Nantong Yichen Biopharma. Co. Ltd. IMMUNOCYTOTIN, ITS PRODUCTION AND ITS USE
CN114787196A (zh) * 2019-08-29 2022-07-22 南特生物科学公司 修饰的n-810及其方法
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
JP2022549494A (ja) * 2019-09-26 2022-11-25 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ウイルス抗原に結合するｎｋエンゲージャー化合物および使用方法
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
US20230034677A1 (en) * 2019-11-21 2023-02-02 INSERM (Institut National de la Santé et la Recherche (Médicale) Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines
US20210188933A1 (en) * 2019-12-18 2021-06-24 Nantcell, Inc Methods of treating pancytopenia
EP4100425A1 (en) * 2020-02-05 2022-12-14 Novartis AG Cho cell expressing il-15 heterodimers
CN115362169A (zh) 2020-02-11 2022-11-18 Hcw生物科技公司 色谱树脂以及其用途
JP2023519107A (ja) 2020-02-11 2023-05-10 エイチシーダブリュー バイオロジックス インコーポレイテッド 制御性ｔ細胞を活性化する方法
WO2021163369A2 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
JP7734693B2 (ja) 2020-04-29 2025-09-05 イミュニティーバイオ インコーポレイテッド 抗ｃｄ２６タンパク質及びそれらの使用法
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
CA3183673A1 (en) * 2020-06-26 2021-12-30 Robert Allen Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins
US12006507B2 (en) 2020-07-22 2024-06-11 Nantcell, Inc. Electroporation with active compensation
US20230280356A1 (en) * 2020-08-03 2023-09-07 Nantcell, Inc. Drug-specific pharmacokinetic assay for il-15 superagonist
WO2022042576A1 (zh) * 2020-08-27 2022-03-03 盛禾(中国)生物制药有限公司 一种多功能融合蛋白及其用途
WO2022090202A1 (en) * 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15RBβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
KR20230096049A (ko) * 2020-10-26 2023-06-29 싸이튠 파마 편평 세포 암종 치료용 IL-2/IL-15Rβγ 작용제
US20220227867A1 (en) * 2020-12-24 2022-07-21 Xencor, Inc. ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
CN112795543B (zh) * 2021-02-04 2022-09-27 华中农业大学 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用
AU2022217812A1 (en) * 2021-02-05 2023-08-03 Salubris Biotherapeutics, Inc. Il-15 fusion proteins and methods of making and using same
WO2022171196A1 (zh) * 2021-02-11 2022-08-18 兰州大学第二医院 抗cd87抗体及其特异性嵌合抗原受体
CN113106068A (zh) * 2021-03-26 2021-07-13 深圳市先康达生命科学有限公司 一种自分泌IL-15与anti-PD1融合蛋白的免疫细胞
US12180492B2 (en) 2021-06-09 2024-12-31 Immunitybio, Inc. Methods and systems for producing a protein of interest in a plant
US20240391972A1 (en) * 2021-09-23 2024-11-28 Sagittarius Bio, Inc Il-12 and il-15 polypeptides
WO2023086772A1 (en) 2021-11-12 2023-05-19 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
CN115806629A (zh) * 2022-08-03 2023-03-17 深圳市先康达生命科学有限公司 一种自分泌IL-15与anti-CTLA4结合的融合蛋白及其应用
CN115806628A (zh) * 2022-08-03 2023-03-17 深圳市先康达生命科学有限公司 一种自分泌IL-15与anti-TIGIT结合的融合蛋白及其应用
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b
CN116789837B (zh) * 2023-03-24 2024-02-23 山西纳安生物科技股份有限公司 一种抗组织因子人源化抗体及制备的抗体偶联药物和应用
CN116574192A (zh) * 2023-03-30 2023-08-11 上海妙聚生物科技有限公司 一种可条件性释放并激活的细胞因子融合蛋白及其制备和用途
WO2024263698A1 (en) * 2023-06-22 2024-12-26 Memorial Sloan-Kettering Cancer Center Anti-pd-l1 immunoglobulin-related compositions comprising il-15-il-15ra fusion polypeptides and uses thereof
WO2025085672A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Bispecific antibodies that bind to nkp46 and mica/b
CN120118196A (zh) * 2023-12-08 2025-06-10 百奥泰生物制药股份有限公司 融合蛋白及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545397A (ja) 2005-05-17 2008-12-18 ユニバーシティ オブ コネチカット 生物におけるイムノモデュレーションのための組成物および方法
JP2010527919A (ja) 2007-05-11 2010-08-19 アルター・バイオサイエンス・コーポレーション 融合分子及びｉｌ−１５変異体
JP2010531878A (ja) 2007-06-27 2010-09-30 マリン ポリマー テクノロジーズ，インコーポレーテッド ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
JP2013541335A (ja) 2010-09-21 2013-11-14 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
JP2015521592A (ja) 2012-06-18 2015-07-30 ノバルティス アーゲー 安定化されたｇｐ１２０
JP2015534982A (ja) 2012-10-18 2015-12-07 ザ ロックフェラー ユニバーシティー 広域中和抗ｈｉｖ抗体
WO2016154003A1 (en) 2015-03-20 2016-09-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to gp120 and their use

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1975A (en) 1841-02-12 Manner of constructing corn-shellers
JPS5291285A (en) 1976-01-23 1977-08-01 Hitachi Ltd Escalator
JPS5841623B2 (ja) 1978-12-25 1983-09-13 株式会社東芝 質量分析装置のイオン検出器
JPS5718916A (en) 1980-07-11 1982-01-30 Iseki Agricult Mach Shaking table sorter of automatic feeding type thresher
JPS5770185A (en) 1980-10-21 1982-04-30 Kazuo Makino Preparation of blended oil for coal liquefaction
JPS57144287A (en) 1981-03-02 1982-09-06 Toray Ind Inc Cyclopentabenzofuran derivative
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1994004689A1 (en) 1992-08-14 1994-03-03 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
AU680909B2 (en) 1994-04-06 1997-08-14 Immunex Corporation Interleukin-15
WO1995027722A1 (en) 1994-04-06 1995-10-19 Immunex Corporation Interleukin-15
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US7008624B1 (en) 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
CA2252557A1 (en) 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center, Inc. Antagonists of interleukin-15
EP0971728B1 (en) 1997-02-21 2002-12-11 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Use of interleukin-15
AU2001261585B2 (en) 2000-05-12 2006-08-31 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
CN101712721A (zh) 2000-06-05 2010-05-26 阿尔托生物科学有限公司 T细胞受体融合物及共轭物以及其使用方法
DE60138222D1 (de) 2000-09-14 2009-05-14 Beth Israel Hospital Modulierung von il-2 und il-15 vermittelten t zellantworten
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
WO2004028339A2 (en) 2002-09-27 2004-04-08 Brigham And Women's Hospital, Inc. Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
EA015897B1 (ru) 2003-02-26 2011-12-30 Генмаб А/С Применение человеческого моноклонального антитела к ил-15 в составе композиции и лекарственного препарата (варианты), композиция и лекарственный препарат, его включающие
DE10324708A1 (de) 2003-05-30 2004-12-16 Ltn Servotechnik Gmbh Schleifringelement und Verfahren zu dessen Herstellung
CN1233822C (zh) 2003-09-05 2005-12-28 中国科学技术大学 白细胞介素－15基因修饰的自然杀伤细胞株及其制备方法
CN1901839A (zh) 2003-11-10 2007-01-24 阿尔特生物科学公司 可溶性tcr分子及其用途
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
EP1586585A1 (de) 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
CN100334112C (zh) 2004-10-15 2007-08-29 上海海欣生物技术有限公司 人白细胞介素15与Fc融合蛋白
DK1814580T3 (en) 2004-11-24 2016-12-12 Hutchinson Fred Cancer Res Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
RU2007126553A (ru) 2004-12-13 2009-01-20 Цитос Биотехнологи Аг (Ch) Упорядоченные ряды антигенов ил-15 и их применение
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
SI1873166T1 (sl) 2006-06-30 2011-01-31 Conaris Res Inst Ag IZBOLJĹ ANI sgp 130Fc DIMERJI
US7965180B2 (en) 2006-09-28 2011-06-21 Semiconductor Energy Laboratory Co., Ltd. Wireless sensor device
PT2856876T (pt) 2007-03-30 2018-03-28 Memorial Sloan Kettering Cancer Center Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos
AU2013273643C1 (en) 2007-05-11 2016-08-11 Altor Bioscience Corporation Fusion molecules and il-15 variants
CA2691539C (en) 2007-06-21 2014-08-26 Angelica Therapeutics, Inc. Modified toxins
US7837588B2 (en) 2007-07-20 2010-11-23 American Axle & Manufacturing, Inc. Pre-load mechanism for helical gear differential
US20110070191A1 (en) 2008-03-19 2011-03-24 Wong Hing C T cell receptor fusions and conjugates and methods of use there of
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014028776A1 (en) 2012-08-15 2014-02-20 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
CA2888896A1 (en) 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
WO2015109124A2 (en) * 2014-01-15 2015-07-23 Kadmon Corporation, Llc Immunomodulatory agents
CN112494646A (zh) 2014-06-30 2021-03-16 阿尔托生物科学有限公司 基于il-15的分子及其方法和用途
CN104672325A (zh) 2015-03-11 2015-06-03 福建农林大学 一种用新鲜螺旋藻制备藻蓝蛋白的方法
AU2016326575A1 (en) 2015-09-25 2018-04-12 Altor Bioscience Corporation Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
JP7037506B2 (ja) 2016-05-27 2022-03-16 アルター・バイオサイエンス・コーポレーション Ｃｄ３結合ドメインを有する多量体ｉｌ－１５系分子の構築及び特性評価
KR20190091264A (ko) 2016-10-21 2019-08-05 알토 바이오사이언스 코포레이션 다량체 il-15 기반 분자
EP3773657A4 (en) 2018-03-26 2021-12-08 Altor Bioscience LLC ANTI-PDL1, IL-15 AND TGF BETA RECEPTOR COMBINATION MOLECULES

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008545397A (ja) 2005-05-17 2008-12-18 ユニバーシティ オブ コネチカット 生物におけるイムノモデュレーションのための組成物および方法
JP2010527919A (ja) 2007-05-11 2010-08-19 アルター・バイオサイエンス・コーポレーション 融合分子及びｉｌ−１５変異体
JP2010531878A (ja) 2007-06-27 2010-09-30 マリン ポリマー テクノロジーズ，インコーポレーテッド ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
JP2013541335A (ja) 2010-09-21 2013-11-14 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
JP2015521592A (ja) 2012-06-18 2015-07-30 ノバルティス アーゲー 安定化されたｇｐ１２０
JP2015534982A (ja) 2012-10-18 2015-12-07 ザ ロックフェラー ユニバーシティー 広域中和抗ｈｉｖ抗体
WO2016154003A1 (en) 2015-03-20 2016-09-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to gp120 and their use

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Ｊ． Ｂｉｏｌ． Ｃｈｅｍ．， ２００６， Ｖｏｌ．２８１， Ｎｏ．３， ｐｐ．１６１２－１６１９
Ｊ． Ｂｉｏｌ． Ｃｈｅｍ．， Ｐｕｂｌｉｓｈｅｄ ２０１６．０９．２０， Ｖｏｌ．２９１， Ｎｏ．４６， ｐｐ．２３８６９－２３８８１
Ｊ． Ｃｌｉｎ． Ｏｎｃｏｌ．， ２０１６， Ｖｏｌ．４， Ｎｏ．１５ ｓｕｐｐｌ， ｐ．５５３３
Ｊ． Ｉｍｍｕｎｏｌ．， ２００８， Ｖｏｌ．１８０， ｐｐ．２０９９－２１０６
Ｎａｔｕｒｅ， ２０１４， Ｖｏｌ．５１５， ｐｐ．５５８－５６２

Also Published As

Publication number Publication date
JP2019533449A (ja) 2019-11-21
CA3200275A1 (en) 2018-04-26
CN110799528A (zh) 2020-02-14
MX2019004681A (es) 2019-10-07
EP4613776A2 (en) 2025-09-10
IL266100B (en) 2022-10-01
IL266100B2 (en) 2023-02-01
AU2017345791B2 (en) 2020-10-22
BR112019007920A2 (pt) 2019-10-08
US11369679B2 (en) 2022-06-28
WO2018075989A1 (en) 2018-04-26
US11318201B2 (en) 2022-05-03
CA3041310C (en) 2023-09-05
IL266100A (en) 2019-06-30
US20210196821A1 (en) 2021-07-01
SG11201903306SA (en) 2019-05-30
CN110799528B (zh) 2024-06-14
EP3529263A4 (en) 2020-07-08
US20200261575A1 (en) 2020-08-20
CN118562016A (zh) 2024-08-30
EP3529263A1 (en) 2019-08-28
CA3041310A1 (en) 2018-04-26
EP4613776A3 (en) 2025-11-26
US20180200366A1 (en) 2018-07-19
KR20210062749A (ko) 2021-05-31
KR20190091264A (ko) 2019-08-05
EP3529263B1 (en) 2025-08-06
AU2017345791A1 (en) 2019-05-09
KR102392142B1 (ko) 2022-04-28

Similar Documents

Publication Publication Date Title
US11318201B2 (en) Multimeric IL-15-based molecules
JP7720950B2 (ja) Ｉｌ－１２及びｉｌ－１８へのｉｌ－１５系融合
US11168138B2 (en) Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
EP3464352B1 (en) Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
CN106659775A (zh) 基于il‑15的分子及其方法和用途
HK40014316A (en) Multimeric il-15-based molecules
HK40014316B (en) Multimeric il-15-based molecules
HK40007105A (en) Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
HK40007105B (en) Construction and characterization of multimeric il-15-based molecules with cd3 binding domains

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220801

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220801

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220816

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220921

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220926

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221014

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240517

R150 Certificate of patent or registration of utility model

Ref document number: 7492336

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150